Summary of END Fund financial information (October 2016)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
Still loading...
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
What are we estimating?How are we estimating it?What is the estimate?Other considerations
2
3
Available and expected funding:
4
5
Total revenue available for 2017 expenses (excluding GiveWell-influenced funding)Average of revenue available for funding expenses (i.e., excluding pledges for future years) in each 2014 and 2015$12,122,119The END Fund told us in October 2016 that it had secured $6.1m for grantmaking and $2.2m for central costs for 2017. Our estimate implies that the END Fund will raise an additional $3.8m for 2017, excluding GiveWell-influenced funds.
6
Percentage of spending on grant-making in 2017Average of percentage of spending on grant-making in 2014 and 201576%The END Fund told us that it expected that for additional funding, 18% would be spent on costs other than grant-making. This may not be inconsistent with the number here, which is for the organization as a whole, rather than for marginal funds.
7
Total available for grant-making in 2017 (excluding GiveWell-influenced funding)Assume that the END Fund will continue to spend the same proportion of its funding on grant-making and other costs as it did on average in 2014 and 2015$9,176,975This implies that the END Fund will spend $2.9m on central costs. The END Fund told us that it expected to spend $4m on central costs in 2017; however, this discussion was part of a conversaton about the END Fund's maximum room for more funding, so this may have referred to the amount it would spend on central costs if it increased its grant-making signficantly.
8
9
Uses of additional funding:
10
11
Total identified deworming grant-making opportunitiesList provided by END Fund with GiveWell adjustments (see 'Deworming opportunities' sheet)$11,733,500In most cases, if SCI, Deworm the World, or Sightsavers also told us about an opportunity, we included the opportunity in those organizations' room for more funding and excluded it from the END Fund's.
12
Total non-deworming grant-making that the END Fund would chose to do if it had an expanded deworming budget (assumes the END Fund has a pool of unrestricted funding)Assuming (1) the END Fund maintains level of support to non-deworming programs; (2) ratio of number of non-deworming treatments to deworming treatments is the same as ratio of non-deworming grant-making to deworming grant-making in 2016 (this is because we have data on number of treatments for each but not on total grant-making for each).$6,500,428Of the funding the END Fund has secured, $2 million is restricted to onchocerciasis, $1.5 million to deworming and the rest is unrestricted or with very broad restrictions.
13
Total of identified deworming grant-making opportunities and maintaining other grant-makingSum of previous two rows$18,233,928
14
Non-grant-making costs at expanded budgetThe END Fund's estimate$4,000,000We're not highly confident that we're interpreted this estimate correctly. See cell D7.
15
Possible deworming grantmaking that END Fund has identified as of Oct. 2016 and maintaining non-deworming grantmakingSum of previous two rows$22,233,928
16
17
Prioritzation of funding gaps:
18
19
Execution level 1Possible deworming grantmaking that END Fund has identified as of Oct. 2016 and maintaining non-deworming grantmaking$22,233,928
20
Execution level 250% more deworming grantmaking$5,866,750Rough intuitive guess
21
Execution level 3100% more deworming grantmaking$5,866,750Rough intuitive guess
22
Total$33,967,428
23
24
Cumulative funding needed for each level:
25
26
Execution level 1See formula$10,111,810
27
Execution level 2See formula$15,978,560
28
Execution level 3See formula$21,845,310
29
30
Assumed uses of secured and expected funding:
31
32
Deworming grant-makingAssume same ratio as previous years$4,995,123
33
Other NTD grant-makingAssume same ratio as previous years$4,181,852
34
Non-grant-making expensesSee formula$2,945,144
35
36
Assumed uses of marginal funding in execution level 1:
37
38
Deworming grant-makingSee formula$6,738,37767% of total
39
Other NTD grant-makingSee formula$2,318,57623% of total
40
Non-grant-making expensesSee formula$1,054,85610% of total
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
 
 
 
Room for more funding summary
Data and calculations
Deworming opportunities
Number of treatments
Grants made